SLE-DAS remission and low disease activity states discriminate drug from placebo and better health-related quality of life.

SLE-DAS remission and LDA showed discriminant ability for identifying patients receiving active drug in SLE clinical trials. Attainment of these SLE-DAS targets are associated with better HR-QoL.